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The gene regulatory network (GRN) of naïve mouse embryonic stem cells (ESC) must be 
reconfigured to enable lineage commitment. TCF3 sanctions rewiring by suppressing 
components of the ESC transcription factor circuitry. However, TCF3 depletion only delays, 
and does not prevent, transition to formative pluripotency. Here we delineate additional 
contributions of the ETS-family transcription factor ETV5 and the repressor RBPJ. In response 
to ERK signalling, ETV5 switches activity from supporting self-renewal and undergoes 
genome relocation linked to commissioning of enhancers activated in formative epiblast. 
Independent up-regulation of RBPJ prevents re-expression of potent naïve factors, TBX3 and 




ESC, such that they remain largely undifferentiated and locked in self-renewal even in the 
presence of differentiation stimuli. Thus genetic elimination of three complementary drivers of 
network transition stalls developmental progression, emulating environmental insulation by 
small molecule inhibitors.  
INTRODUCTION 
Mouse embryonic stem cells (ESC) are in vitro cell lines that retain a high degree of molecular 
and functional correspondence with the naïve pluripotent epiblast of the pre-implantation 
embryo (Boroviak et al., 2014; Bradley et al., 1984; Evans and Kaufman, 1981; Martin, 1981). 
Accordingly, they provide a rich resource for studying mechanisms underlying developmental 
decisions and transitions. In particular, the ESC pathway to differentiation in vitro provides an 
opportunity to dissect the progression of pluripotency from naïve founder cells through to 
specification of germline and somatic lineage progenitors. 
Culture in the presence of two small molecule inhibitors (2i) that suppress the MEK/Erk 
pathway and glycogen synthase kinase-3 (GSK3) sustains  stable expression of transcription 
factor components of the naïve pluripotency gene regulatory network (GRN) (Dunn et al., 
2014; Wray et al., 2010; Ying et al., 2008). ESC in these serum-free conditions are proposed 
to reside in a regulatoryground state (Ying et al., 2008). Upon release from 2i, ESC transition 
into a distinct second stage of pluripotency that we have termed “formative” (Kalkan and Smith, 
2014; Smith, 2017). Formative pluripotent cells have lost GRN components diagnostic of naïve 
pluripotency and gained transcription factors characteristic of the peri-implantation epiblast 
such as POU3f1, OTX2, and LEF1. Functional ESC identity is extinguished concomitant with 
change in transcription factor complement (Kalkan et al., 2017). In parallel, epigenetic 
processes such as DNA methylation are up-regulated, and competence is gained for lineage 
induction (Hayashi et al., 2011; Mulas et al., 2017) and onward progression to primed 
pluripotency. The naïve to formative conversion in a simple and well-defined culture 
environment simulates events in the peri-implantation mouse embryo (Kalkan et al., 2017), 
and provides a sensitised platform for identifying factors and mechanisms that mediate change 
in cell identity (Buecker et al., 2014; Kalkan and Smith, 2014). 
Genetic screens have identified several genes that promote ESC transition (Betschinger et 
al., 2013; Leeb et al., 2014; Li et al., 2018; Villegas et al., 2018; Yang et al., 2012). TCF3 
(gene name Tcf7l1) was the first factor identified (Guo et al., 2011b) and is recurrently 
recovered. TCF3 represses key naïve transcription factors ESRRB, TFCP2L1, NANOG and 
KLF2 (Martello et al., 2012; Pereira et al., 2006), an effect blocked by GSK3 inhibition in 2i 
culture (Wray et al., 2011). Other pathways and factors identified in the screens have also 
been shown to reduce expression or function of components of the naïve GRN, although to a 
lesser extent than Tcf3. Strikingly, the majority of these components are present in naïve ESC 
but are ineffective in 2i (Kalkan and Smith, 2014). The pre-existence of multi-layered 
dissolution machinery means that mouse ESC are poised for rapid disabling of the naïve 
network. Multiple effectors also explain why single factor mutants only delay and do not 
prevent transition.  
However, while elimination of naïve factors is necessary for departure from the ESC state, it 
may not be sufficient for installation of an alternative GRN, which requires new transcription 
factor expression and enhancer reconfiguration (Buecker et al., 2014; Factor et al., 2014; Yang 
et al., 2014). MEK/ERK inhibition is the second component of 2i. ERK1/2 signalling likely 
contributes directly to naïve GRN destabilisation (Jin et al., 2016; Kim et al., 2014; Yeo et al., 
2014), but its role in ESC transition to multi-lineage competence (Kunath et al., 2007; Stavridis 
et al., 2007) is also anticipated to include transcriptional activation (Tee et al., 2014; Williams 
et al., 2015). 
 
 
Here we sought to characterise drivers of the naïve to formative transition that might act in 
parallel with TCF3, and examine whether genetic deletions might replace 2i and maintain 
naive ESC self-renewal. 
 
RESULTS 
Identification of ETV5 as a candidate driver of progression from naïve to formative 
pluripotency  
To identify factors that may mediate the effect of MEK/ERK inhibition in driving pluripotency 
network transition we inspected results from loss-of-function screens. Among transcription 
factors, we noted that Etv5 is the most recurrent hit after Tcf3 in a random mutagenesis screen 
(Leeb et al., 2014), and is a high confidence candidate from a genome-wide siRNA screen 
(Yang et al., 2012). ETV5 is a member of the PEA3 sub-family of ETS transcription factors, 
along with Etv1 and Etv4 (Hollenhorst et al., 2011b; Oh et al., 2012). ETV5 and other ETS 
factors are typically activated by FGF/ERK signalling through transcriptional upregulation 
and/or protein phosphorylation (Janknecht et al., 1996; Oh et al., 2012; Selvaraj et al., 2015). 
ETV5 is considered to be functionally redundant with ETV4 and the two factors are co-
expressed in multiple tissues in response to FGF (Liu et al., 2003; Mao et al., 2009; Zhang et 
al., 2009) or GDNF (Lu et al., 2009).  
Etv5 transcripts are readily detected in ground state ESC (Fig 1A). In contrast Etv4 mRNA is 
not evident in 2i, but is rapidly up-regulated in transitioning cells. Transcripts for both factors 
are detected in mouse naïve (E4.5) and formative (E5.5) epiblast, with ETV5 being more 
abundant (Fig 1B). Etv1 expression is negligible in ESC and the early embryo. We examined 
in closer detail the behaviour of Etv5 and Etv4 in ESC upon transfer from 2i to N2B27. 
Ribosome profiling indicated potential for a truncated ETV5 protein isoform (N-Etv5) lacking 
the first 202 amino acids (Ingolia et al., 2011) that include an N-terminal transactivation domain 
(N-TAD) (Defossez et al., 1997; Laget et al., 1996). Accordingly, we designed alternative RT-
qPCR primer pairs. We detected the ETS domain but not the N-TAD encoding sequence in 
undifferentiated ESC, indicating expression of N-ETV5 only. In contrast, N-TAD-containing 
transcripts appear within 4h after 2i withdrawal and persist for 48 hours (Fig 1C). Total Etv5 
transcripts increase initially but decline from 24 hours, implying down-regulation of N-Etv5. 
Etv4 expression also rises rapidly on removal of 2i, then reduces. We investigated steady 
state Etv4/5 expression in ESC maintained with single inhibitors and LIF. Both canonical Etv5 
and Etv4 mRNA are up-regulated in conditions when ERK signalling is active (Fig 1D).  
Inspection of RNA-seq and H3K4me3 ChIP-seq data substantiated activity of an internal Etv5 
promoter in undifferentiated ESC, whereas transcripts originating from the upstream start site 
are evident after 2i withdrawal (Fig S1A). Immunoblotting identified a smaller N-Etv5 protein 
(Figs1E, S1B) that decreased from 24hrs of transition. Conversely, the canonical isoform was 
absent from undifferentiated cells and up-regulated over the transition time course. Single 
inhibitor withdrawal showed that canonical Etv5 is expressed in response to MEK/ERK 
activation. siRNA mediated knock-down confirmed the specificity of immunoblotting (Fig S1B).  
Etv5 fulfils distinct roles in ESC self-renewal and transition  
Due to the proposed redundancy between Etv5 and Etv4, we first sourced ESC genetically 
deficient for both genes (E4/5-dKO) (Lu et al., 2009). These cells were derived in serum and 
LIF and reported to show reduced proliferation (Akagi et al., 2015). This phenotype is 
exacerbated in 2i/LIF (Fig S1C). However, we found that the mutant cells could be expanded 
robustly by omitting the MEK inhibitor and culturing in CH/LIF (Fig S1C). We therefore 
maintained E4/5-dKO cells in CH/LIF, but for consistency with previous studies (Kalkan et al., 
 
 
2017; Mulas et al., 2017) cells were exchanged into 2i prior to assay. A short period of 2i 
culture has no apparent effect on growth rate or viability (Fig S1C). The assay entails 
withdrawal of 2i for 48h before replating at clonal density in CH/LIF (Fig 1F). Self-renewal 
capacity is almost entirely extinguished in parental ESC by 48h. In contrast, E4/5-dKO cells 
still generate numerous undifferentiated colonies (Fig 1G). This phenotype is eliminated upon 
expression of cDNA encoding either isoform of Etv5 (Fig 1G), both of which also rescue the 
growth defect during self-renewal (Fig S1C).  
To discriminate functions of Etv4 and Etv5, we employed CRISPR/Cas9 to create single and 
double knock-outs. We used RGd2 ESC that carry the Rex1::GFPd2 knock-in reporter of naïve 
status (Kalkan et al., 2017). Etv5-KO ESC also show reduced expansion in 2i or 2i/LIF but 
proliferate normally in CH/LIF (Fig S1D). These results indicate that Etv5 plays a specific role 
in consolidating naïve ESC propagation when MEK/ERK signalling is blocked and Etv4 is not 
expressed. We expanded cells in CH/LIF and transferred into 2i before assay, as above. Etv4 
mutants show no significant delay in GFP downregulation (Fig 1H) or extinction of 
clonogenicity (Fig 1I). In contrast, deletion of Etv5 results in impaired exit from naïve 
pluripotency, measured by perdurance of GFP and persistence of clonogenic cells. Normal 
GFP down-regulation was restored by expressing either Etv5 isoform (Fig S1E). In Etv5 
mutants Etv4 is activated later, but to an enhanced level (Fig S1F). However, the Etv5-KO 
phenotype is not enhanced in E4/5-dKO ESC (Fig 1H), confirming that Etv4 has little relevance 
for kinetics of transition from 2i.  
These results establish that Etv5 supports ESC self-renewal when ERK signalling is inhibited, 
and facilitates exit from naïve pluripotency when ERK is active. Although canonical Etv5 is 
specifically up-regulated prior to exit, either isoform can be sufficient for both functions.  
Co-deletion of Etv5 and Tcf3 retards but does not prohibit exit from naïve pluripotency  
Tcf3 is upregulated in Etv5-KO ESC indicating that the phenotypes are independent (Fig S2 
A, B). As Tcf3 is downstream of GSK3 and Etv5 is regulated by ERK1/2, we tested whether 
combined deletion of both genes might mimic the effect of 2i and be sufficient to sustain ESC 
self-renewal. We generated Etv5/Tcf3 single and double mutants in RGd2 ESC and compared 
GFP profiles after transfer into N2B27 (Fig 1J). In double knockout (ET-dKO) cells, perdurance 
of GFP was more pronounced. However, at the end of passage 2 ET-dKO cells showed a 
substantial fraction of GFP low/negative cells, and undifferentiated ESC were not sustained 
after replating (Fig 1J). Thus TCF3 and ETV5 act combinatorially to drive pluripotency 
progression, but the absence of both is not sufficient to prevent loss of ESC identity.  
Deletion of Rbpj delays naïve state exit  
We re-inspected the candidate regulators to identify a factor that might complement ETV5 and 
TCF3 to enforce exit from naïve pluripotency. The repressor RBPJ was detected in a haploid 
ESC mutagenesis screen (Leeb et al., 2014). RBPJ is expressed in the naïve epiblast in the 
embryo (Fig S2C). RBPJ is nuclear localized in ESC (Fig 2A) and RBPJ mRNA and protein 
are up-regulated upon 2i withdrawal, a response that is enhanced in Etv5-KO and Tcf3-KO 
cells (Figs S2D-F). RBPJ is therefore a candidate complementary regulator, regulated by both 
ERK and GSK3, and acting through uncharacterised targets.  
We inactivated Rbpj in RGd2 ESC using CRISPR/Cas9. Rbpj deficient ES cells adopted a 
more flattened colony morphology but showed no markers of differentiation (Fig S2G) growth 
in 2i remained similar to parental ESC (Fig S2H). Upon withdrawal from 2i, Rbpj-KO cells 
exhibit delayed down-regulation of Rex1-GFPd2 and persistence of clonogenic ESC at 42hrs, 
consistent with siRNA results (Leeb et al., 2014) (Fig 2B, C). Rex1 down-regulation timing is 
restored upon expression of an Rbpj transgene, which also rescues domed colony morphology 
(Fig S2G, I). 
 
 
RBPJ is best known for a role in the NOTCH pathway in which activated NOTCH intracellular 
domain induces a switch from repression to activation of target genes (Kopan and Ilagan, 
2009). However, RBPJ can also regulate genes independently of NOTCH (Castel et al., 2013; 
Johnson and Macdonald, 2011). Absence of most known NOTCH transcriptional targets (Fig 
S2J), despite detectable expression of NOTCH ligands and pathway components (Fig S2K), 
suggests that the NOTCH pathway may not be significant during naive ESC transition. 
Nonetheless, to test if NOTCH might be relevant to exit dynamics, we employed -secretase 
inhibitors to block production of NOTCH intracellular domain. We did not observe any effect 
on Rex1-GFP down-regulation (Fig S2L). Thus RBPJ may act purely as a repressor during 
naïve state exit. 
By RNA-seq we found 405 upregulated and 705 downregulated genes in Rbpj-KO ESC in 2i 
(padj ≤0.05, FPKM≥1) (Table S1), with functions in multiple processes (Fig S3A, D). Since 
Rbpj deletion did not affect ESC self-renewal (Fig S2H), we focussed on differential expression 
during transition. At 16h after 2i withdrawal (N16h), 2341 genes were up- and and 355 down-
regulated (Table S1). KEGG pathway analysis shows enrichment in both 2i and N16h for cell 
adhesion, focal adhesion and ECM-receptor interactions (Fig S3A, B), reflected in expression 
of laminins, integrins, collagens and cadherins (Fig S3C). This is in line with observations in 
Rbpj mutant fibroblasts (Castel et al., 2013) and likely explains the morphology of Rbpj-KO 
ESC. Formative pluripotency markers Lef1, Dnmt3b and Pou3f1 fail to be up-regulated (Figs 
2D, S3E). Reduced expression of FGF/MAPK pathway components and NOTCH receptors is 
also evident. Among the top upregulated genes are targets of canonical NOTCH signalling 
known to be repressed by RBPJ, including Id1, Id3, Id4 and Hes1 (Main et al., 2010; Meier-
Stiegen et al., 2010) (Figs 2D, S3E, S4A). Repressed targets of Hes1 (Kobayashi et al., 2009), 
are among the top downregulated genes, consistent with increased Hes1 levels. ID factors 
and HES1 have previously been shown to impede ESC differentiation (Davies et al., 2013; 
Kobayashi and Kageyama, 2010; Ying et al., 2003; Zhou et al., 2013). Id3 is highly expressed 
in Rbpj mutants (FigS4A). CRISPR/Cas9 mediated mutation of Id3 in RGd2 ESC slightly 
diminished GFP levels and appeared to accelerate downregulation. However, Id3 knockout 
did not restore exit kinetics in Rbpj-KO ESC (Fig S4B). We also mutated Hes1 and found no 
effect (Fig S4C).  
To widen the search for relevant targets we examined pluripotency factor expression in Rbpj 
mutants and noted that Tbx3 and Nanog are among the top 200 up-regulated genes during 
transition (Figs 2D, F). A previous ChIP-seq study reported these genes amongst candidate 
RBPJ targets in F9 embryonal carcinoma cells (Lake et al., 2014). We employed ChIP-PCR 
to examine RBPJ binding at the reported Nanog and Tbx3 sites and confirmed localisation 
proximal to both genes (Figs 2F, G, S4D). Furthermore, there is a palindromic RBPJ binding 
motif (Castel et al., 2013) within the binding site at the Nanog transcriptional start site (Fig 2F). 
We used siRNA to knock down Nanog and Tbx3 in Rbpj mutants and found in both cases that 
exit kinetics and clonogenicity are almost fully restored (Fig 2H, I). We also tested the effect 
of these knockdowns in Etv5 mutants (Fig S4E). NANOG depletion reverts the Etv5-KO exit 
delay phenotype, reflecting its general importance for sustaining naïve pluripotency, whereas 
TBX3 siRNA has little or no effect, indicating that its role is specific to the RBPJ context. 
These data indicate that up-regulation of RBPJ promotes extinction of naïve pluripotency 
principally by extinguishing expression of Nanog and Tbx3. Interestingly, intersection of the 
ChIP-seq data with transcriptome data from Rbpj-KO cells identified 401 potential directly 
repressed genes (Fig S4F, Table S2), including additional genes associated with ES cell self-
renewal notably the LIF signal transducer STAT3. Significantly, however, only 8 of these 
candidates overlap with high confidence TCF3 repressed targets (Fig S4G, Table S2) 






Elimination of Etv5 and Rbpj allows self-renewal supported only by GSK3 inhibition  
In light of their independent regulation (Fig S2A-F), we created combined mutants for both 
Etv5 and Rbpj (ER-dKO), and Rbpj and Tcf3 (RT-dKO). Double mutants show a stronger 
phenotype, but undifferentiated ESC cannot be expanded beyond two passages in N2B27 
(Fig 3A). However, deficiency for Etv5 and Rbpj is sufficient to sustain self-renewal in GSK3 
inhibitor (CH) only. Parental ESC cannot be propagated in these conditions beyond passage 
2 (Fig 3B). Both single mutants can also be maintained in CH (Fig S4H), but expand slowly 
(Fig S4I), whereas ER-dKO cells proliferate similarly to parental RGd2 cells in 2i (Fig S4I) and 
remain uniformly GFP-positive (Fig 3B). After 5 passages in CH, we assayed colony formation 
in 2i/LIF as a measure of naïve ESC frequency. ER-dKO cells generated undifferentiated 
colonies with undiminished efficiency relative to RGd2 cells maintained in 2i (Fig 3C,D-a,b). 
Furthermore, they could also form colonies robustly in CH (Fig S4J), a property that is lost in 
parental ESC after 2 passages. These results demonstrate a combined effect of Etv5 and 
Rbpj deletion that enables self-renewal without MEK inhibition or LIF. 
Triple deletion of Etv5, Rbpj and Tcf3 renders ESC self-renewal constitutive  
We then generated triple knockouts for Etv5, Rbpj and Tcf3 (ETR-tKO). Like Rbpj, Tcf3 and 
ER-dKO mutants, ETR-tKO cells were flattened but undifferentiated and uniformly GFP 
positive in CH/LIF (Figs 3E, F, S5A). In contrast to other mutants, two independently generated 
ETR-KO clones maintained robust GFP expression in N2B27 (Fig 3G), expanding constantly 
although more slowly than in CH/LIF (Fig S5B, C). After 10 passages in N2B27, only a minor 
GFP-negative population emerged (Fig 3G). ETR-tKO cells passaged in N2B27 generated 
numerous alkaline phosphatase positive colonies on replating at clonal density in 2i/L and also 
in N2B27 only (Fig 3C,D-c,d). Immunostaining of ER-dKO cells in CH and ETR-tKO cells in 
N2B27 showed relatively homogeneous staining for OCT4 and for naïve pluripotency factors 
NANOG and TFCP2L1 (Fig 3H). Under neural differentiation conditions, ETR-tKO cells 
maintained Nanog and Klf4 protein expression with no induction of neural markers SOX1 or 
TuJ1 (Fig 3I).  
We examined whether conversion to primed EpiSC (Brons et al., 2007; Guo et al., 2009; Tesar 
et al., 2007) is impeded in the various mutants. Cells were transferred to medium containing 
Activin, Fgf2 and Wnt pathway inhibitor XAV939 (Sumi et al., 2013), hereafter AFX. Over 3 
passages RGd2 lines converted into epithelial EpiSC with complete loss of GFP but retention 
of alkaline phosphatase (Fig 4A-C). Tcf3-KO and Rbpj-KO mutants similarly converted 
efficiently to EpiSC. In contrast, Etv5-KO cells down-regulated GFP (Fig 4B), but displayed 
distinct morphology by passage 2 (Fig 4A-c, d). By passage 3 cultures differentiated into 
fibroblast-like cells (Fig 4A-e, f) and contained only occasional patches of alkaline 
phosphatase positive cells (Fig 4C). Only one culture eventually yielded with EpiSC-like cells 
and these cells deviated from the EpiSC state, with lower expression of Pou3f1 and almost no 
Fgf5 or Otx2 (Fig 4D). In contrast to all the above, ETR-tKO mutants retained a significant 
proportion of GFP cells, even after 10 passages in AFX (Fig 4E). They maintained substantial 
expression of naïve markers Klf2 and Tfcp2l1 with low expression of Otx2, Pou3f1 and Fgf5 
(Fig 4D).   
We examined embryoid body formation in serum, an inductive system for multilineage 
differentiation (Doetschman et al., 1985). Single mutants down-regulated naïve markers but 
failed to up-regulate the mesoderm marker Pax3 or neural marker Pax6 (Fig 4F). Endoderm 
markers were less affected, but this may reflect extraembryonic differentiation without 
formative transition (Smith, 2017). In ETR-tKO cells upregulation of formative and lineage 




We investigated whether paracrine signalling might contribute to ETR-KO cell resistance to 
transition. We labelled ETR-tKO cells with the monomeric Kusabira Orange (mKO) reporter 
and set up mixed cultures with a minority (5%) of RGd2 test cells. GFP downregulation kinetics 
were unaltered (Fig S5D), demonstrating that the ETR-tKO phenotype is cell intrinsic. 
Finally, we introduced a transgene for re-expression Etv5 and Tcf3 in ETR-tKO mutants.  
Doxycycline induced expression was lower than endogenous wild type levels, but cells 
initiated downregulation of Rex1 and Nanog, and upregulation of Pou3f1 (Fig S5E, F). After 3 
days in N2B27 alone, NANOG protein was absent from a high proportion of Dox-treated cells 
while it remained uniformly expressed in untreated cells (Fig S5G). This rescue experiment 
indicates that the transition delay phenotype is reversible and directly attributable to the 
mutated genes. 
Whole transcriptome analysis of Etv5/Rbpj and Etv5/Tcf3/Rbpj mutant ESC  
We performed RNA-seq (Table S3) and compared mutant cells with RGd2 cultures in 2i, 
N2B27 for 16h or 72h (N16h or N72h), or CH for 2 passages (CHp2). At 16h ESC are poised 
for transition but will regenerate ESC colonies at high efficiency if restored to 2i/LIF (Kalkan et 
al., 2017). Hierarchical clustering (Fig 5A) divides N72h and CHp2 from other samples, 
consistent with having exited the ESC state. ETR-tKO cells cultured in N2B27 and ER-dKO 
cells in CH form a sub-cluster between 2i and N16h samples. Principal component analysis 
(PCA) discriminates on PC1 samples before and after exit (Fig 5B), while PC2 separates 2i 
from transitional cells. ETR-tKO cells are close to 2i samples but displaced towards N16h.  
Pluripotency factor profile is similar between ETR-tKO and naïve ESC, with some modulation 
in levels (Fig 5C). Expression of some formative markers is detectable, but at levels below 
those in N16h cells. Lineage markers are absent or very lowly expressed (Fig 5D; Tables S2, 
S3). As in Rbpj single mutants, NOTCH targets, focal adhesion and ECM genes are 
upregulated, along with actin cytoskeleton components (Fig 5E, F). MEK/ERK pathway 
components and targets are upregulated while expression of Wnt target genes is reduced, in 
line with absence of 2i (Fig 5E, F). Several metabolism and lysosome related genes are 
downregulated, which may relate to slower growth of ETR-tKO cells (Fig S5F).  
These results establish that the naïve pluripotency factor network is intact and the transition 
to formative pluripotency is barely initiated, both for Etv5/Rbpj mutants cultured in CH and for 
triple mutants in N2B27 only.  
Triple knock out cells colonise chimaeras but do not convert to post-implantation 
epiblast  
We then examined whether ETR-tKO cells retain functional proximity to naïve epiblast. We 
introduced a constitutive H2B‐tdTomato reporter and performed injections into 8 cell embryos 
that were then cultured to the expanded blastocyst stage. In 9/9 blastocysts, mutant cells 
extensively colonised the epiblast, outnumbering the host cells similarly to parental RGd2 cells 
(Fig 6A). Contribution was confined to the Sox2 positive epiblast, with no cells detectable in 
primitive endoderm or trophoblast. Thus ETR-tKO cells retain the ability of undifferentiated 
ESC to survive, proliferate, and colonise the epiblast exclusively (Alexandrova et al., 2016).  
We then examined behaviour of ETR-tKO cells in post-implantation development following 
uterine transfer of injected embryos. Mutant cells were present in 20/20 embryos recovered at 
E6.5 and E7.5. Unlike RGd2 chimaeras, which showed distribution of ESC progeny throughout 
the egg cylinder epiblast, most of the embryos injected with mutant cells had abnormal or 
rudimentary egg cylinders (see Table S4 for phenotypes and numbers). Mutant cells did not 
intermingle with host cells (Fig 6B-D). They retained expression of Rex1-GFPd2 and of Nanog, 
 
 
and failed to up-regulate T (Brachyury) or Pou3f1. In some cases ETR-tKO contributions were 
large and extended beyond the embryonic/extraembryonic boundary (Table S4).  
We conclude that triple mutant cells are unable to adopt identity of post-implantation epiblast 
and consequently cannot respond to inductive signals for germ layer specification. Persistence 
in a naïve-like state disrupts development of the host epiblast.  
ETV5 regulates network components of both naïve and formative pluripotency  
To illuminate how ETV5 regulates both self-renewal and transition we performed RNA-seq 
and ChIP-seq in 2i and N16h. We identified 754 ChIP-seq peaks in 2i and 1020 at N16h, with 
only 392 in common (Table S5, Fig 7A). Thus there is a major change in ETV5 genome 
location early in the ESC transition process. As observed in other cell types for ETV5 and ETS 
factors in general (Hollenhorst et al., 2007; Zhang et al., 2017), ETV5 peaks were enriched at 
promoters (Fig S6A). RNA-seq in 2i revealed 77 down-regulated genes (FC≤0.67) and only 
eight upregulated genes (FC≥1.5) associated with ETV5 peaks (Fig S6B, Table S6)), 
consistent with function of N-ETV5 as a transcriptional activator. Targets include genes with 
potential roles in proliferation and maintenance of ESC (Fig S6B): Sall1 (Novo et al., 2016); 
E2f2 (Wang and Baker, 2015); Id3 (Ying et al., 2008); and most notably Klf5, which supports 
robust ESC proliferation (Ema et al., 2008). Activation of these genes may explain the 
contribution of ETV5 to ESC expansion. On the other hand, ETV5 binding is also detected at 
genes encoding transcription factors and epigenetic regulators associated with ESC transition 
or recovered in exit screens (Fig S6B). By priming transcription of these genes, ETV5 may 
prepare naive cells for rapid progression. Curiously, Otx2 was upregulated in Etv5-KO cells in 
2i, although this was not sustained during transition (Figs S6B, S7A). 
At N16h we found ETV5 binding proximal to 163 (FC ≥ 1.5) of 3672 up-regulated genes (padj 
≤0.05, FPKM≥1) (Fig S6C, Table S6). These include transcription factors, components of 
H3K4 methyltransferase complex, negative regulators of Ras/ ERK pathway, and Tgf- 
pathway members. Id3 and some naïve transcription factors, are also represented. These data 
present the possibility that ETV5 might participate in transcriptional repression by an unknown 
mechanism and thereby contribute to shutting down the naïve GRN. Intersection with TCF3 
and candidate RBPJ repressed targets showed limited overlap (Fig S6D). 
Among 346 downregulated genes at 16h, 16 are associated with proximal ETV5 binding (Fig 
7B). These include genes in metabolic pathways and involved in calcium signalling. This is of 
note because metabolic resetting is an early feature of ESC transition (Fiorenzano et al., 2016; 
Kalkan et al., 2017; Zhou et al., 2012). Prominent formative pluripotency markers Lef1, Fgf5 
and Pou3f1 are also represented. ETV5 binds to enhancers associated with these three genes 
(Fig 7C-E). The enhancers are activated in EpiLC (Buecker et al., 2014), a transient population 
obtained by plating ESC in Activin/Fgf2/KSR for 48h (Hayashi et al., 2011). We found that 
ETV5 remains bound in EpiLC (Fig S7B). Etv5 mutants show impaired Rex1 downregulation 
(Fig 7F) and reduced expression of the three genes in EpiLC culture (Fig 7G). Furthermore, 
gain of H3K27Ac at the enhancers is diminished in mutants (Fig 7H), suggesting that ETV5 
may promote H3K27 acetylation.  
We used CRISPR/Cas9 to mutate Pou3f1 and Lef1 (Fig S7C). However, in neither single nor 
double mutants did we observe a delay in exit (FigS7D). The marker profile of Lef1/Pou3f1 
double mutants at 48h was also similar to parental RGd2 cells, although a modest reduction 
in Sox2, Sox3 and Fgf5 was apparent (Fig S7E). We also noted that ETV5 binds to the Oct4 
proximal enhancer that is required for expression in post-implantation epiblast (Fig S7F)(Yeom 
et al., 1996), and found that Oct4 expression was maintained at ES cell levels during mutant 
cell conversion to EpiLC (Fig S7G). We then examined potential wider-reaching actions of 
ETV5. We partitioned non-promoter ETV5 peaks, which include enhancers, into 3 groups: 2i 
 
 
only; N16h only; shared. Across these regions we computed levels of chromatin marks 
associated with active enhancers; H3K27Ac, H3K4me1 and p300, from (Buecker et al., 
2014)(Fig 7I). We found that 2i-specific ETV5-bound regions lose H3K27Ac and p300 upon 
conversion to EpiLC, whereas across 208 loci that gain ETV5 at 16h, there is a marked 
increase in H3K27Ac and p300 in EpiLC. A more modest gain in H3K27Ac is apparent across 
shared regions. Thus ETV5 relocates from naïve pluripotency-specific enhancers to 
formative/EpiLC enhancers upon 2i withdrawal. In contrast, promoters associated with ETV5 
are largely devoid of p300 and show loss of H3K27Ac in EpiLC (Fig S7H). ETV5 binding is 
coincident with p300 at enhancers (Figs 7C-E, I). This is of note because p300 has been 
shown to acetylate ETV1 and ETV4, increasing transactivation potential (Goel and Janknecht, 
2003; Guo et al., 2011a), a mechanism likely also to operate for ETV5. Depletion of p300 has 
an ESC transition delay phenotype (Leeb et al., 2014), consistent with p300 and ETV5 
cooperating to commission formative enhancers. 
DISCUSSION 
This study demonstrates that elimination of two transcriptional repressors and one activator 
effectively prohibits mouse ESC progression to lineage competence. TCF3, RBPJ and ETV5 
serve complementary and partially overlapping functions in driving exit from the ESC ground 
state and initiation of formative pluripotency. Cells lacking all three factors are trapped in an 
ESC-like condition from which they can only rarely escape, even in the presence of strong 
differentiation stimuli.  
Absence of TCF3 permits ESC propagation in MEK inhibitor alone (Wray et al., 2011), while 
combined deletion of ETV5 and RBPJ sustains self-renewal with GSK3 inhibition only. Triple 
knock out cells are liberated from requirement for both inhibitors and exhibit constitutive self-
renewal. These cells are stalled at a very early stage in transition. They retain uniform 
expression of naïve pluripotency factors and high clonogenicity. Robust colonisation of the 
naïve epiblast demonstrates they remain functionally within the ESC compartment. However, 
ETR-tKO cells cannot advance from this state even in the powerful inductive environment of 
the post-implantation embryo. These observations are consistent with evidence that ES cells 
may self-renewal autonomously if differentiation is prevented. 
TCF3 is well characterised as an ESC regulator (Cole et al., 2008; Guo et al., 2011b; Pereira 
et al., 2006; Wray et al., 2011). RBPJ by contrast has not previously been studied in this 
context. RBPJ is known to repress Hes1 and Id genes, factors that can delay or reverse 
pluripotency progression in ESC cultured in serum or BMP (Davies et al., 2013; Ying et al., 
2003). In the peri-implantation embryo, RBPJ may counterbalance BMP to curtail persistence 
of naïve epiblast. However, during defined in vitro transition the critical contribution of up-
regulated RBPJ is to extinguish expression of naïve factors, in particular Nanog and Tbx3, 
and prevent re-ignition of the naïve GRN. Elimination of Tbx3 may also be important to restrict 
potency for extraembryonic endoderm (Lu et al., 2011). 
Combined deletion of Etv4 and Etv5 compromises proliferation and differentiation of ESC 
(Akagi et al., 2015). We find that both phenotypes are primarily attributable to Etv5. This is in 
line with post-implantation lethality by E8.5 of ETV5 ETS domain deletion (Lu et al., 2009), 
while Etv4-null mice are viable (Arber et al., 2000; Laing et al., 2000). Etv5 mutant mice that 
carry an N-terminal deletion are also viable (Chen et al., 2005), supporting functionality of N-
Etv5. N-ETV5 may have altered signal sensitivity and partner interactions, which may be of 
relevance in cancers in which PEA3 family members are frequently mis-expressed (de Launoit 
et al., 2006; Hollenhorst et al., 2011a). N-ETV5 supports ESC propagation when ERK 
signalling is inhibited, potentially via direct regulation of Klf5. When ERK is active in self-
 
 
renewal conditions, ETV5 is dispensable, likely due to activation of an alternative ETS factor 
such as ETV4 or GABPA.    
During naïve GRN collapse, ETV5 pivots from supporting naïve ESC propagation to activating 
the formative pluripotency programme. Absence of ETV5 derails installation of the formative 
GRN and also impedes exit from naïve pluripotency. This phenotype is distinct from Tcf3 and 
Rbpj mutants, in which there is a delay in exit but no major compromise in subsequent 
transition or formation of EpiSC. However, mutations in peri-implantation epiblast factors 
implicated in formative pluripotency, such as Pou3f1 and Lef1, do not substantially delay naïve 
state exit. Initial handover to the formative GRN may therefore be specifically dependent on 
ETV5. We surmise that in the absence of ETV5, the network switch is not initiated and cells 
transiently retain, or revert to, naïve status. Under influence of TCF3 and RBPJ they eventually 
exit, but then mostly succumb to miscellaneous differentiation or death, although there is some 
rescue by ETV4 or other pathways.  
PEA3 factors are known as transcriptional activators (Oh et al., 2012). Interestingly, even in 
ground state ESC, N-ETV5 may prime transcription of some early transition genes (Fig S6B). 
Upon 2i withdrawal, ETV5 occupies new genome locations, many associated with enhancers 
that become active during or after transition. ETV5 is phosphorylated by active ERK1/2 and is 
a probable target for acetylation by p300. These effects likely lead to the observed relocation 
whereby ETV5 can rapidly contribute to commissioning the formative GRN.  
ETR-tKO cells retain core features of ESC identity but operationally appear nullipotent 
because they are unable to execute the formative transition. We conclude that timely and 
correct developmental progression from naïve pluripotency is determined by three functions: 
TCF3 triggers dissolution of the naïve GRN; RBPJ enforces exit by preventing reversion; ETV5 
commissions the successor formative GRN. Additional regulators contribute (Betschinger et 
al., 2013; Kalkan and Smith, 2014; Leeb et al., 2014; Li et al., 2018), but these three effects 
may be the major drivers. Speed and efficiency depend on temporal coordination and it is 
striking that all three components are already present in naïve ESC, although levels and 
activity change during transition. It will be of interest to compare with mammals that have 
prolonged pluripotency progression, including primates (Nakamura et al., 2016; Smith, 2017). 
Future research will also reveal whether dissolution, enforcement, and initiation actions may 
commonly be combined to provide a triple lock for secure cell state transition.  
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Main Figure Legends 
Figure 1. Etv4/5 expression and function 
(A,B) RNA-seq expression values (FPKM or RPKM) for naïve and transitioning ESC, and 
early embryo lineages. Error bars represent standard deviation (SD) from (A) 2 and (B) 3 
independent biological replicates. 
(C,D) RT-qPCR expression in 2i and after 2i withdrawal, and in 2i/L components for 3 
passages. Data are means +/- SD from: (C) 2 wells of cells differentiated in parallel; (D) 3 
independent biological replicates. L=LIF, CH= CHIR99021, P= PD0325901.  
(E) Western blot with anti-Flag antibody on Etv5-3XFLAG knock-in ESC.  
(F) Schematic for panels G-I.  
(G) Quantitation of colony assays on WT (wild-type), Etv4/5-dKO ESC, and Etv4/5-dKO ESC 
expressing monomeric Kusabira Orange (mKO), ΔN-Etv5 or canonical Etv5 transgenes. 
Error bars show SD from 2 technical replicates. 
(H) Rex1-GFP profiles of RGd2 and independently generated clonal lines (c) of Etv4-KO; 
Etv5-KO and Etv4/5-dKO at 25 and 42 hours post-2i withdrawal. RGd2-2 is a clonal line 
derived from parental RGd2-1.  
(I) Colony assay.  
(J) GFP profiles for parental RGd2 and mutant ESC lines at 72h post-CH/LIF withdrawal 
(N72h) and end of passage 2 (p2). Red cross indicates failure of replating after passage. 
ET= Etv5/Tcf3.  
See also Figures S1 and S2. 
 
Figure 2. Rbpj expression and function  
(A) Rbpj Western blot: T= total cell lysate, C= cytoplasmic fraction, N= nuclear fraction. Oct4 
and GAPDH were used as loading controls for nuclear and cytoplasmic fractions, 
respectively.  
(B) GFP profiles of RGd2 and three clonal Rbpj mutant lines in N2B27 at 25h (N25h) and 
42h (N42h) post-2i withdrawal.  
(C) Colony assay.  
(D) MA-plot showing mean expression against fold change per gene in Rbpj-KO ESCs at 
16h post-2i withdrawal (N16h). Gene symbols and coloured tags are shown for selected 
genes listed.  
(E) RNA-seq expression values for naïve pluripotency factors in RGd2 and Rbpj-KO ESC in 
2i and at N16h. Error bars show SD from biological replicates plated in parallel; 3 
independent clonal lines for Rbpj-KO, 2 different lines for RGd2 (one parental and one 
clonal) 
(F) UCSC genome browser tracks for Nanog and Tbx3 loci showing normalized RNA-seq 
read coverage for parental and Rbpj-KO ESC at N16h. RBPJ binding sites are indicated with 
red arrowheads. The RBPJ-binding motif within the Nanog locus is highlighted.  
(G) ChIP-qPCR for binding sites shown in Fig 2F and Fig S4E.  Two primer sets were used 
for the Tbx3 locus. Y axis shows absolute enrichment normalized to input DNA for each 
sample. Error bars indicate SD from two ChIP replicates.  
(H) GFP profiles at 40h after 2i withdrawal following a 7-hour period of siRNA transfection.  
(I) Colony assay at 40h after 2i withdrawal.  





Figure 3. Dual and triple knock out phenotypes 
(A) GFP profiles of RbpJ-KO (R-KO), Etv5/Rbpj-dKO (ER-dKO), Rbpj/ Tcf3-dKO (RT-dKO) 
ESC at 72h post-CH/LIF withdrawal (N72h) or at the end of passage 2 (p2). Red crosses 
indicate failure of replating upon passage.  
(B) Profiles of RGd2 and ER-dKO ESCs cultured in CHIRON (CH) only.  
(C, D) Clonogenicity in 2i/LIF or N2B27. Error bars show SD from 2 technical replicates. 
(E) GFP Profiles of ETR-tKO and RGd2 ESCs cultured in CH/LIF. 
(F) Phase contrast images. Scale bar= 75µM.  
(G) GFP Profiles of ETR-tKO ESCs cultured in N2B27 only 
(H) Immunofluorescent staining (IF) of RGd2 ESCs cultured in 2i, ER-dKO in CH and ETR-
tKO in N2B27 after 6 passages.  
(I) IF after 8 days of neural differentiation. 
Images were taken using 20x (H) and 10x (I) objective. 
See also Figures S4 and S5. 
 
Figure 4. Transition failure of Etv5 and triple knock out ESC 
(A) Phase contrast images of RGd2 and Etv5-KO ESCs during first three passages (p1-3) in 
AFX taken using a 10x objective. Scale bar= 75µM.  
(B) GFP profiles at the end of p1  
(C) Alkaline phosphatase staining at the end of p3  
(D, E) RT-qPCR and GFP profiles after 10 passages in AFX  
(F) RT-qPCR on embryoid bodies on days 3-9. Day 0 is starting ESC in CH/LIF. Error bars in 
D and F show SD from 2 technical replicates for qPCR . 
 
Figure 5. Transcriptome analysis of single and combined mutants 
(A, B) Hierarchical clustering and PCA plot based on normalized gene expression for all 
genes.  * denotes cells expanded in CH/LIF and switched to 2i for 48hrs prior to sample 
conditions.  
(C, D) Heatmaps showing relative expression for: pluripotency genes; lineage markers. 
Values are shown as Log2 fold change of RNA-seq read counts relative to RGd2 2i-p5. Only 
the genes with a mean expression value of FPKM≥1 in either RGd2 2i-p5 or ETR-tKO N-p5 
samples were included. Genes were sorted by mean expression within each group.  
(E) KEGG pathway enrichment for differentially expressed genes.  
(F) MA-plot showing mean expression against fold change per gene in ETR-KO cells 
cultured in N2B27 for 5 passages (ETR-tKO N-p5) vs RGd2 2i-p5 sample. Gene symbols 
are shown for selected genes listed below. 
See also Tables S2, S3. 
 
Figure 6. Chimaera contribution and perturbation by triple knock out ESC 
Reporter fluorescence and whole mount immunofluorescence staining on chimeric embryos 
obtained from RGd2 or ETR-tKO ESCs labelled with H2B-tdTomato (red). 
(A) In vitro matured blastocysts at E4.5 stained for Gata4 and Sox2. Scale bar=50µm.  
(B) E6.5 embryos with T (Brachyury) staining and Rex1-GFP fluorescence. Arrowheads in 
the lower DAPI panel point to separate ETR-tKO chimeras. Scale bar=100µm.  
(C) E7.5 embryos with Pou3f1 (Oct6) and Nanog staining. Scale bar=200µm  
(D) E7.5 T and Nanog staining. Scale bar=200µm.  
Note the different magnifications for RGd2 and ETR-tKO chimeras in C and D. 




Figure 7. Etv5 association with transcriptionally dynamic genes 
(A) Numbers of ETV5 ChIP-seq peaks in 2i or at 16h post-2i withdrawal (N16h).  
(B) Heatmap showing relative expression of downregulated genes in Etv5 mutants (fold  
≤0.66) at 16h post-2i withdrawal (N16h) with associated Etv5 binding.  
(C-E) UCSC Genome browser tracks showing normalized ChIP-seq  read coverage for Etv5 
and H3K4me3 (this study), p300, H3K27Ac and H3K4me1 (Buecker et al , 2014).  
(F) GFP profiles of EpiLCs (48h in Activin/Fgf2/KSR) generated from RGd2 ESCs or ETV5-
KO ESCs (2 clonal lines).  
(G) RT-qPCR on time course samples during EpiLC formation. Error bars show SD from 2 
wells of cells differentiated in parallel. 
(H) ChIP-qPCR showing H3K27Ac levels on upstream and downstream loci adjacent to the 
Etv5 peaks shown in C-E. Y-axis shows absolute enrichment normalized to input DNA from 
each sample. ChIP was performed in duplicate (1 and 2) for each sample. Error bars show 
SD from 2 qPCR replicates.  
(I) Mean read coverage for p300, H3K27Ac and H3Kme1 (ChIP-seq from Buecker et al, 
2014) on “non-promoter”-associated ETV5-bound loci. Read depth scaled to 1x. 


































Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the Lead Contact Austin Smith, austin.smith@cscr.cam.ac.uk 
 
Experimental Model and Subject Details 
Mice used in these studies were adult females aged 6-10 weeks. The CD1 strain was used to 
provide embryos and CBA/BL6 F1 animals were employed as transfer recipients. Animals in 
the facility tested positive for Helicobacter but negative for other specific pathogens. Studies 
were performed in a UK Home Office designated facility in accordance with EU guidelines for 
the care and use of laboratory animals, and under authority of a UK Home Office project 
licence. Use of animals in this project was approved by the Animal Welfare and Ethical Review 
Body for the University of Cambridge.  
ES cell culture  
Since Etv5-KO ESCs cannot be cultured long-term in the presence of PD, for consistency 
across experiments presented in this paper and with previous studies (Kalkan et, al 2017, 
Mulas et al, 2017), all cell lines were routinely cultured in CH/LIF then exchanged to 2i or 
2iLIF for a total of 48hrs before the assay. For CH/LIF cultures, ES cells were plated at 1x 
104 cells cm-2 in CH/LIF on plates coated with 0.1% Gelatine (Sigma-Aldrich, G1890). Media 
was refreshed every other day and cells were passaged every 3 days. For passaging, cells 
were dissociated with Accutase (Millipore, SCR005) for 5 mins, 5-10x volume of wash buffer 
[DMEM/F12, 0.03% BSA Fraction V (Thermofisher)] was added, cells were spun and 
resuspended in fresh CH/LIF. Culture media used in the experiments consisted of N2B27 
(made in house) supplemented with CH/LIF, 2i (CH/PD) or 2i/LIF at the following final 
concentrations: PD0325901 (PD), 1 μM; CHIR99021 (CH), 3 μM; LIF (prepared in house), 
1:1000.  To calculate growth rates, cell lines were plated at equal density, and counted at the 
end of each passage using a Vi-CELL Automated Cell Viability Analyzer (Beckman-Coultier).  
Monolayer differentiation, clonogenicity assays and flow cytometry 
For analyses of kinetics of exit from naïve pluripotency, CH/LIF cultures were exchanged to 
2i for 24hrs, dissociated with Accutase, plated in 2i at 1.5 x 104 cells cm-2  and cultured for 
24hrs prior to withdrawal of inhibitors. For flow cytometry, ESCs were dissociated using 
Accutase and diluted 1:5 in FACS buffer [PBS, 5% FBS]. ToPro-3 (Invitrogen) was added at 
a concentration of 0.05 nM to label membrane-compromised cells. Flow cytometry was 
performed on a Dako Cytomation CyAn ADP high-performance cytometer, using the same 
voltage settings for all experiments and results were analyzed with Flowjo. Representatives 
GFP profiles from at least 2 independent experiments are shown throughout the paper. For 
clonogenicity assays, cells were dissociated at 40-48h post-2i withdrawal and following 
resuspension in appropriate media, cells were plated at single cell density (~500 cells/ 6-
well) in 2i/LIF or CH/LIF on plates coated with 1% Laminin (Sigma, Cat. L2020) in duplicate. 
At day 6 alkaline phosphatase staining was performed using AP Kit (Sigma-Aldrich). Plates 
were scanned using Cell Celector (Aviso) and colonies were scored manually.  
Notch Inhibition 
RGd2 ES cells were treated with γ-secretase inhibitors DBZ (CAS 209984-56-5, 
Calbiochem) or DAPT (565770, Merck) at the concentrations shown in figure legends. 




Plates were coated with Laminin (~10µg/ml in PBS) for at least 4 hours to overnight at 37°C. 
Laminin was aspirated and ESCs were plated directly in N2B27 onto laminin-coated plates 
at a density of 1.0x104 cells/cm2. N2B27 was refreshed on day 2 and every day thereafter. 
ES cell to EpiSC conversion and EpiSC culture 
ES cells were plated in N2B27 supplemented with Activin A (20ng/ml), Fgf2 (12.5ng/ml) and 
XAV939 (1μM) on Fibronectin-coated (Millipore, FC010) plates at a density of 1x104 cells/ 
cm2. Media was refreshed on the 2nd day and cells were passaged every 3 days using 
Accutase (Millipore, SF006). To enhance plating efficiency ROCK-inhibitor Y27632 (1mM) 
was included for the first 6-12 hours following plating and then removed. 
Differentiation of ES cells in embryoid bodies (EB) 
Single EBs per well were generated by sorting 1500 ES cells using a MoFLo Flow Sorter 
(Beckman Coultier) into a well of PrimeSurface96U plates (Sumitomo Bakelite)  containing  
GMEM supplemented with GMEM, L-Glutamine (2mM), NEAA, Sodium Pyruvate (1mM), 
non-essential amino acids, β-Mercaptoethanol (100mM) (Life Technologies)  and 15% FCS 
(Hyclone). Twelve EBs were pooled for assay. 
Generation of Knock-Out ES cell lines using CRISPR-Cas9-mediated mutagenesis 
gRNAs were cloned into PX459 (hSpCas9-2A-Puro) vector. Two gRNAs targeting different 
exons of a gene were co-transfected into Rex1-GFPd2 ESCs (Kalkan et, 2017) using 
FuGENE HD (Promega). Transfected cells were selected using Puromycin (0.5-1μg/ml) 
between 14h- 86h post-transfection. Clones were picked on day 9, expanded in CH/LIF and 
assayed by qRT-PCR to detect the genomic deletion.  Details of gRNAs and qPCR primers 
are included in Table S7. 
Genetic rescue of Etv5-KO, Rbpj-KO, ETR-tKO ES cell lines 
cDNAs encoding Tcf3, Rbpj and long and short forms of Etv5 were amplified from total 
cDNA of RGd2-N16h samples.  Rbpj and Etv5 isoforms were cloned into a PiggyBac vector 
containing a PGK-Hygromycin selection cassette and a CAG promoter to drive constitutive 
transgene expression. To generate stable “rescue” ES cell lines, 1x106 Knock-Out ES cells 
were co-transfected with PiggyBac constructs (20ng) and PiggyBac transposase (400ng) 
using 1.5 µl FuGENE HD(Promega) for 14h in CH/LIF in one well of a 6-well dish. From 24h- 
post-transfection cells were cultured in Ch/LIF with Hygromycin (160µg/ml). For inducible 
expression of Etv5 and Tcf3 in ETR-tKO ESCs, an Etv5-p2A-Tcf3 transgene was generated 
by PCR and cloned into a PiggyBac vector containing a PGK-Hygromycin selection cassette 
and a TRE3G promoter to drive Doxycycline-inducible transgene expression. 3x105 ETR-
tKO ES cells were co-transfected with this expression construct (50ng), a CAG-Tet3G-IRES-
zeocin construct (50ng) and PiggyBac transposase (100ng), using 1µl FuGENE HD 
(Promega) for 14h in Ch/LIF in one well of a 6-well dish. From 24h-post-transfection cells 
were cultured with 20µg/ml Zeocin and 160µg/ml Hygromycin. Experiments were performed 
after at least 10 days of selection of stable transfectants with antibiotics. Doxycycline 
(100ng/ml) was added to culture media to induce transgene expression. 
Generation of mKO- and H2B-TdTomato-labelled ESCs 
1x106 RGd2 and ETR-tKO ESCs were transfected as above with a Piggybac construct 
carrying CAG-driven monomeric Kusabira Orange (mKO) (20ng) and a PGK-Hygromycin 
selection cassette together with PiggyBac Transposase (400ng) and stable transfectants 
were selected with Hygromycin (160 ng/ml). For TdTomato labelling,  1x106 ESCs were 
transfected with CAG-driven H2B-TdTomato-IRES-Puro construct using 10µl FuGene in one 




RGd2 and Rbpj-KO ESCs cultured in CH/LIF were switched to 2i for 24hrs before siRNA 
transfection. Cells were dissociated and resuspended in 2i. 6x104 cells were mixed with 700 
µl 2i, 1µl Lipofectamine RNAiMax (Thermofisher) and 2 independent siRNAs for Tbx3 or 
Nanog or both, at a final concentration of 1.25nM each, and plated in a well of a 24-well 
tissue culture plate. AllStars negative control siRNA (Qiagen) was used as control. After 
7hrs, medium was replaced with N2B27 to initiate differentiation. Please see Table S7 for 
siRNA catalog numbers. 
Immunofluorescence (IF) staining of ES cells  
Cells were fixed for 10 min with 4%PFA at RT, followed by permeabilization and blocking in 
blocking buffer [PBS, 0.1% TritonX-100, 3% donkey serum] for 2hrs at RT. Cells were 
incubated with primary antibodies in blocking solution overnight at 4 °C, using dilutions 
shown in Table S7. Alexa Fluor-conjugated donkey secondary antibodies (Molecular Probes) 
were used at 1:1000 dilution and were incubated with cells for 1hr at RT. Cells were washed 
with PBS/0.1% TritonX-100 three times for 5mins after primary and secondary antibody 
incubations.  Images were obtained using a Leica 4000B standard fluorescent microscope 
using a 10x or 20x objective as indicated in the figure legends. 
RNA extraction, cDNA synthesis and qPCR 
Total RNA was isolated using Relia Prep RNA Miniprep System (Promega). cDNA was 
synthesized using GoScript Reverse Transcriptase System (Promega) and oligo-dT primers. 
qRT-PCR was performed with TaqMan Gene Expression (Thermo Scientific) or  Universal 
Probe Library (Roche) assays. Expression levels were normalized to GAPDH for all 




Western blot and sub-cellular fractionation of total cell lysate 
To obtain total cell lysate cells were lysed in 1xPBS supplemented with 1%TritonX-100, 
0.1%SDS, protease and protein inhibitors (Roche) and sonicated briefly in the Bioruptor 
(Diagenode) to shear the gDNA. Extraction of nuclear and cytoplasmic fractions  was 
performed with NEPER Nuclear and Cytoplasm Extraction Reagents (ThermoFisher 
Scientific). Blots were blocked with blocking solution (1xPBS, 1%TritonX-100, 5% skimmed 
milk) for 2hrs at RT, followed by incubation with primary antibodies for 2hrs at RT or 
overnight at 4 °C. Primary antibodies and dilutions are listed in Table S6. For detection 
IRDye secondary antibodies (Licor) were used at 1:2000- 1:5000 dilution and signal 
intensities were quantified by Odessey (Licor). Antibodies and primer/probes sets are listed 
in Table S6. 
Chromatin immunoprecipitation (ChIP) and ChIP-seq library preparation 
ESCs were dissociated with Accutase, washed with culture medium (10x volume) and 
resuspended in fresh culture medium at 5x106 cells per ml.  To cross-link chromatin, for 1ml 
of cell suspension 100µl of Fix Solution [0.1M NaCl, 1mM EDTA, 0.5mM EGTA, 50mM 
HEPES pH 7.5, 11% Formaldehyde] was added, and cells were rotated for 10min at RT. To 
neutralize the formaldehyde, 157µl 1M Glycine was added, and cells were rotated for 5min 
at RT, followed by spin at 1600g for 5min. Cells were then washed with 1ml ice-cold 
PBS/BSA 0.03% and spun, repeating 3 times. Protease /Phosphatase inhibitors (Roche) 
were added in the last wash. Cells were either frozen at -80°C at this point or processed 
immediately. To obtain nuclear lysates, pellets from 5x106 fixed cells were resuspended in 
ice-cold 1ml buffer LB1 [50mM HEPES pH 7.5, 140mM NaCl, 1mM EDTA, 10% glycerol, 
0.5% NP40, 0.25% Triton-X100], rotated for 10min at 4°C, spun at 1600g for 5min, 
resuspended in ice-cold 1ml buffer LB2 [10mM Tris pH 8.0, 200mM NaCl, 1mM EDTA, 
0.5mM EGTA], rotated for 10min at 4°C, spun at 1600g for 5min and resuspended in 140µl 
shearing buffer [1% SDS, 10mM EDTA, 50mM Tris pH 8.0]. Nuclear Lysates were sonicated 
with Bioruptor (Diagenode) at High setting, for 26 cycles (30sec ON / 30sec OFF) to obtain 
DNA fragments with an average size of 300bp. Lysates were spun in a microcentrifuge at 
8°C at maximum setting for 10mins to remove debris. 130 µl of supernanatant (equivalent of 
approximately 5x106 cells) was diluted in 1300 µl 11x dilution buffer [50mM Tris pH 8.0, 
167mM NaCl, 1.1% Triton X-100, 0.11% Na-Deoxycholate]. Lysates were frozen at -80°C at 
this point or processed immediately. 1430 µl diluted nuclear lysate (equivalent of 
approximately 5x106 cells)  was pre-cleared by incubating with 2-4µg of isogenic normal IgG 
and 25µl Protein G  Dynabeads (Invitrogen, 1004D) on a rotator at 4°C for 2 hrs. 
Supernatants were then incubated with the appropriate ChIP antibody (see Table 6 for 
dilutions) on a rotator overnight at 4°C, followed by incubation with 30µl Protein G 
Dynabeads for 1h at 4°C. To remove unbound chromatin and unspecific interactions, beads 
were washed two times with Wash Buffer 1 [50mM Tris pH 8.0, 0.1% SDS, 0.1% Na-
Deoxycholate, 1% Triton X-100, 150mM NaCl, 1mM EDTA, 0.5mM EGTA], one time with 
Wash Buffer 2 [50mM Tris pH 8.0, 0.1% SDS, 0.1% Na-Deoxycholate, 1% Triton X-100, 
500mM NaCl, 1mM EDTA, 0.5mM EGTA], one time with Wash Buffer 3 [50mM Tris pH 8.0, 
250mM LiCl, 0.5% Na-Deoxycholate, 0.5% NP-40, 1mM EDTA, 0.5mM EGTA] and two 
times with Wash Buffer 4 [50mM Tris pH 8.0, 10mM EDTA, 5mM EGTA]. Each wash was 
performed for 5mins on a rotator using ice-cold buffers and protease/phosphatase inhibitors 
(Roche). Chromatin-antibody complexes were eluted by incubating in 125µl of Elution Buffer 
[1% SDS, 0.1M NaHCO3] on a shaker block at 37°C for 15mins, repeating twice. Elutions 




The following antibodies and cell numbers were used for each ChIP replicate: H3K4me3 
ChIP,  3x106 cells, 3 µg rabbit H3k4me3 antibody (Diagenode pAb-MEHAHS-024, A1-010); 
H3K27Ac ChIP, 3x106 cells, 2 µg rabbit H3K27Ac antibody (Active Motif, 39159); RBPJ 
ChIP, 5x106 , 4.5 µL polyclonal rabbit RBPJ antibody (Cell Signaling Technology, 5442S), 
Etv5-3xFlag ChIP; 5x106 cells, 3 µg anti-Flag M2 antibody (Sigma-Aldrich). For H3K27Ac 
and RbpJ ChIP, 2µg normal rabbit IgG (Abcam,ab171870) was used for pre-clearing step 
and a different batch of rabbit IgG (Cell Signaling Technology, 2729S) was used for negative 
control samples. Etv5-Flag ChIP was performed on lysates obtained from two independently 
derived clonal ES cell lines (Etv5-Flag-KI-20 and Etv5-Flag-KI-32) that carry a 3xFlag 
epitope knocked in to the C-terminal end of the endogenous Etv5 coding sequence just 
before the stop codon. Parental RGd2 ES cells served as negative control. ChIP-Seq 
libraries were generated using NEB Next ChIP-Seq Library Prep Master Mix Set for Illumina 
(NEB).  
ChIP-seq analysis 
Sequencing reads were mapped to the mm10 mouse reference genome using Bowtie2 
(Langmead and Salzberg, 2012), converted to a density plot and displayed as UCSC 
genome browser custom tracks. ETV5 peaks were called over RGd2 parental line controls 
using MACS2 software (Zhang et al., 2008). Mapped reads were converted to density plots 
and displayed as UCSC genome browser custom tracks. Only the peaks called in both 
biological replicates (p < 10-4) were selected for further analyses. Peaks overlapping a 
promoter (1000+/- RefSeqGene TSS coordinates) by at least 1bp, or a gene body was 
assigned to only that gene. The rest of the peaks (intergenic peaks) were assigned to the 
nearest genes within 50Kb. To identify potential direct targets of Etv5, the peaks were 
intersected with genes that show a fold change of  ≥1.5 in the UP direction and ≤0.66 in the 
DOWN direction in Etv5-KO ESCs over parental RGD2 ESCs. 
H3K27ac, H3K4me1, p300 and input data from Buecker et al, 2014 with accession number 
GSE56138 were downloaded from the NCBI Gene Expression Omnibus. The reads were 
aligned to the mm10 reference genome using bowtie (-y -m 1 --best --strata --nomaqround) 
and converted to bigwig using deeptools 6(Ramirez et al., 2016) bamCoverage (--
extendReads 200 --binSize 1 --normalizeTo1x 2150570000). The mean signal at the ETV5 
peaks was extracted using Deeptools computeMatrix using the ETV5 peak centers as 
reference points. 
Transcriptome sequencing (RNA-seq) 
RNA-seq was performed in triplicates per condition, including three independently derived 
clonal lines per genetic knock-out, and two RGd2 lines as wild type controls. Exception is 
RGd2-N16h samples for which only 2 replicates were sequenced, as one was lost during 
library preparation. RGd2-2 is a clonal line derived from the parental RGd2 line (RGd2-1).  
Total RNA was extracted with ReliaPrep RNA Miniprep System (Promega) and was 
processed with Ribo-Zero capture probes (Illumina). Libraries were produced using 
NEXTflex Rapid Directional qRNA-Seq Kit  (Bioo Scientific). Libraries were sequenced in the 
Illumina platform in paired-end mode. 
RNA-seq analysis 
Illumina sequencing adapters were removed using Trim Galore! and reads shorter than 20 nt 
were discarded. The reads were aligned to the mouse reference genome (GRCm38/mm10) 
with ERCC spike-ins appended to it. The alignment was done using TopHat2 and Gencode 
(release M14) gene models were used as a guide. Read counts per gene were calculated 
using featureCounts requiring strand-specific, primary and unique matches. Normalization 
and statistical analysis of the resulting counts table was done using the R Bioconductor 
 
 
package DESeq2 using normalization factors based on the spike-in counts. Gene counts 
were converted to fragments per kilobase per million mapped reads (FPKM) and then log2-
transformed for visualization in heatmaps and MA-plots. A significance threshold of 
padj<0.05 and FPKM ≥1 was used to define differentially expressed genes. 
KEGG pathway analysis:  
Enriched KEGG pathways were identified using the 'goseq' package from R Bioconductor. 
Only expressed genes with mean FPKM ≥1 were considered. Differentially expressed genes 
with padj <0.05 and log2 fold change >0.5 or <-0.5 were compared with all expressed genes. 
False discovery rate was calculated to correct for multiple testing using the 'p.adjust' function 
in R. 
Cluster analysis and PCA:  
Regularized log-transformed counts were calculated using DESeq2 and used for sample 
clustering and PCA. Hierarchical clustering was done using the 'pheatmap' package in R 
with sample distances calculated by the 'dist' function. PCA was done by the 'prcomp' 
function without scaling. 
Data and Software Availability 
ChIP-seq and RNA-seq data from this study have been submitted to GEO database with the 
accession number GSE122338. 
Chimaera production  
Pregnant females were killed on day 2.5 post coitum (E2.5) by cervical dislocation. Oviduct 
and uterus were dissected, and flushed with M2 media (Sigma, M7167) using Leica M165C 
microscope system for better visualization. Embryos were collected in M2 media prior to 
microinjection.  E2.5 embryos were transferred into M2 media, covered with a layer of mineral 
oil (Sigma, M8410). Embryos were visualized using an Olympus microscope system and an 
Olympus 40x LWD Plan APO 0.6 NA air objective. ESC were loaded into a microinjection 
pipette and injected into the perivitelline space of 8-cell embryos using Hamilton Thorne 
XYClone microinjection system (Hamilton Thorne). Eight cells were transferred into each 
embryo. Injected embryos were cultured for 2 days in BlastTM media (Origio, 8306001A) at 37 
°C, 20% O2 and 7% CO2. For post-implantation analyses, embryos were transferred one day 
after injections into oviducts of pseudopregnant females. Contribution was characterised at 
E4.5, E6.5 and E7.5. 
Immunofluorescence staining of embryos  
For immunofluorescence analysis of cultured pre-implantation stage embryos, zona 
pellucidae were removed using tyrode acid solution (pH 2.5). Embryos were fixed with 4% 
w/v paraformaldehyde (PFA) (Sigma, P6148) in PBS for 15 minutes at room temperature 
(RT). Samples were washed three times with PBS, supplemented with 3 mg/ml 
poly(vinylpyrrolidinone) (PVP) (Sigma, P0930) (PBS/PVP). For permeabilization, embryos 
were incubated for 30 minutes in 0.25% Triton-X-100 (Sigma-Aldrich, T8787) diluted in 
PBS/PVP. Embryos were incubated for 15 minutes in 2% donkey serum, 0.25% bovine 
serum albumin (BSA) (Sigma, 1076192), 0.01% Tween 20 (Sigma Aldrich, P2287) in PBS, 
followed by overnight incubation in primary antibodies diluted in blocking buffer (Table S6). 
On the next day embryos were washed three times for 15 minutes in blocking buffer before 
incubation for 1h in secondary antibodies diluted in blocking buffer. Afterwards, embryos 
were washed three times for 15 minutes in blocking buffer with or without DAPI.  
Dissected post-implantation stage embryos were fixed for 1 hour in 4% PFA. Embryos were 
washed three times 15 minutes in PBS/PVP. For permeabilization, embryos were incubated 
for 1 hour in PBS containing  5% DMSO (Santa Cruz, sc-358801) , 0.5% Triton-X-100, 0.1% 
BSA and 0.01% Tween20 at 4 °C. Embryos were blocked overnight at 4 °C in humidified 
 
 
environment in permeabilization buffer, containing 2% donkey serum. On the next day 
embryos were incubated overnight at 4°C in primary antibodies (Table S7) in blocking buffer. 
Embryos were washed 3 times for 2 hours in blocking buffer, before incubation overnight in 
secondary antibodies diluted in blocking buffer. Lastly, embryos were washed three times for 
2 hours in blocking buffer with or without DAPI.  
For embryo mounting, samples were taken through a series of 25%, 50%, 75% and 100% 
vectashield (Vector Laboratories, H-1000)  diluted in PBS. Embryos were mounted in a drop 
of vectashield, surrounded by drops of Vaseline as a spacer for the coverslip, to immobilise 
embryos. Coverslips were sealed using nail varnish. Finally, slides were stored at -20°C prior 
to imaging.  
Embryos were imaged using a Leica TCS SP5 confocal microscope. Image acquisition was 
performed with a 20x 0.7NA air objective. For illumination, a 405, 488, 561 and 647 nm lasers 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
pERK p44/42 MAPK (T202/T204) XP® Cell Signaling Technology Cat#4370S 
Etv5 Abcam  Cat#ab102010,  
RRID:AB_10711030 
Flag M2 Sigma-Aldrich Cat#F1804, RRID:AB_262044 
Rbpj Cell Signaling Technology Cat#5442S, RRID:AB_10695407 
Normal rabbit IgG Cell Signaling Technology Cat#2729S 
Normal rabbit IgG Abcam Cat#ab171870 
Normal mouse IgG Santa Cruz Cat#sc-2025 
GAPDH Sigma-Aldrich Cat#G8795, RRID:AB_1078991 
H3K27Ac Active Motif Cat#39135, RRID:AB_2614979 
ERK  Cell Signaling Technology Cat#9107 
Pou3f1 (Oct6) C-20 Santa Cruz Cat#sc-11661 
Lef1 Abcam Cat#ab137872 
GATA4 Santa Cruz Cat#sc1237, RRID: AB_2108747 
Sox2 eBioscience Cat#14-9811-80, RRID: 
AB_11219070 
Tuj1 R&D Systems Cat#MAB1195 
Sox1 Cell Signaling Technology Cat#4194, RRID:AB_1904140 
Klf4 R& D Systems Cat#AF3158, RRID:AB_2130245 
Nanog eBioscience Cat#14-5761-80, RRID:AB_763613 
Tfcp2l1 R& D Systems Cat#AF572,  RRID:AB_2202564 
H3K4me3 Diagenode  Cat#pAb-MEHAHS-024 
GFP ThermoFisher Scientific Cat#A-11122, RRID:AB_221569 
T (Brachyury) R&D Systems Cat#AF2085, RRID:AB_2200235 
Oct4 Santa Cruz Cat#sc-5279, RRID:AB_628051 
b-tubulin Abcam  Cat#ab6046, RRID:AB_2210370 
Bacterial and Virus Strains  
N/A   
   
Biological Samples   
N/A   
   
Chemicals, Peptides, and 
Recombinant Proteins 
MEK inhibitor PD0325901 ABCR Cat#AB 253775 
GSK3 inhibitor CHIR99021  ABCR Cat#AB 253776 
Laminin  Millipore Cat#CC095-5MG 
Fibronectin Millipore Cat#FC010 
ROCK inhibitor Y-27632 Merck Chemicals  
 
Cat#688000-100MG 
Tankyrase inhibitor XAV939 Cell Guidance Systems Cat#SMS38-200 
Activin A Made in house N/A 
Fgf2  Made in house N/A 
LIF  Made in house  N/A 
N2B27 Made in house  N/A 
Key Resource Table
 
Accutase Millipore Cat#SCR005 
Gelatin  Sigma-Aldrich Cat#G1890 
Γ-secretase inhibitor  Calbiochem Cat#CAS 209984-56-5 
Γ-secretase inhibitor DAPT Merck Chemicals Cat#565770 
FuGENE HD transfection reagent Promega E2311 
Critical Commercial Assays 
Alkaline Phosphatase Kit Sigma-Aldrich Cat#86R-1KT 
NEPER Nuclear Cytoplasm Extraction 
Reagents 
ThermoFisher Scientific Cat#78833 
Dynabeads Protein G Thermofisher Scientific Cat#10004D 
   
Deposited Data 
Etv5 ChIP-seq (2i, N16h) This study GSE122338 
H3K4me3 ChIP-seq (2i, N16h) This study GSE122338 
RNA-seq  of Etv5, Rbpj and Tcf3 
single, double and triple mutant ESCs 
This study GSE122338 
   
Experimental Models: Cell Lines 
Rex1-GFPd2 (RGd2) ESC Kalkan et al, 2017 N/A 
Rex1-GFPd2 c1 (RGd2-2) ESC (clonal 
line) 
This study N/A 
Etv5 knock-out ESC (3 clonal lines) This study N/A 
Rbpj knock-out ESC (3 clonal lines) This study N/A 
Tcf3-knock-out ESC (2 clonal lines) This study N/A 
Etv5/Tcf3 double knock-out ESC (2 
clonal lines) 
This study N/A 
Rbpj/Tcf3 double knock-out ESC (2 
clonal lines) 
This study N/A 
Etv5/Tcf3/Rbpj triple knock out ESC (3 
clonal lines) 
This study N/A 
Etv4 knock-out ESC (3 clonal lines) This study N/A 
Etv4/Etv5 knock-out lines (1 clonal 
line) 
This study N/A 
Hes1 knock-out ESC (2 clonal lines) This study N/A 
Id3 knock-out ESC (2 clonal lines) This study N/A 
Lef1 knock-out ESC (2 clonal lines) This study N/A 
Pou3f1 knock-out ESC (2 clonal lines) This study N/A 
Pou3f1/Lef1 double knock-out ESC (2 
clonal lines) 
This study N/A 
RGd2/mKusabira Orange (mKO)  ESC This study N/A 
RGd2/ H2B-tdTomato ESC This study N/A 
ETR-tKO/mKusabira Orange(mKO) 
ESC 
This study N/A 
ETR-tKO/H2B-tdTomato ESC This study N/A 
Etv5-3xFlag knock-in ESCs (2 clonal 
lines) 
This study N/A 
Etv5-KO/Etv5-3xFLAG rescue ESC This study N/A 
Etv5-KO/ΔEtv5-3xFLAG rescue ESC This study N/A  
Etv5-KO/mKusabira Orange (mKO) This study N/A 
Rbpj-KO/Rbpj rescue ESC This study N/A 
 
ETR-tKO/TetG/TRE3G-iEpT ESC This study N/A 
ETR-tKO/TetG ESC This study N/A 
Etv4/Etv5 double knock-out ESC (2 
lines; PE15-3, PE15-4) 
Lu et al, 2009 N/A 
Etv4/Etv5 dKO (PE3/PE4)/ mKusabira 
Orange ESC  
This study N/A 
Etv4/Etv5 dKO (PE3/PE4)/ Etv5-
3xFlag rescue ESC 
This study N/A 
Etv4/Etv5 dKO (PE3/PE4)/  ΔEtv5-
3xFLAG rescue ESC  
This study N/A 
Wild type ESC Lu et al, 2009 N/A 
Experimental Models: 
Organisms/Strains 
Mus musculus females aged 6-10 
weeks: CD1 strain was used to provide 
embryos and CBA/BL6 F1 animals 
were employed as transfer recipients 
for embryo chimaeras. 
N/A N/A 
   
   
   
   
Oligonucleotides 
Nanog siRNA, Mm_Nanog_3 
FlexiTube siRNA 
Qiagen   
Cat#SI01323357 
Nanog siRNA, Mm_LOC100038891_2 
FlexiTube siRNA 
Qiagen Cat#SI04460869 
Tbx3 pre-designed siRNA Assay ID: 
223884 
 
Thermofisher Scientific Cat#AM16708 
 
Tbx3 pre-designed siRNA Assay ID 
223885 
Thermofisher Scientific Cat#AM16708 
 
gRNAs Sequences See Table S7 for sequences  
Taqman and UPL gene expression 
assays 
See Table S7 for oligo 
sequences and catalog 
numbers 
 
ChIP-qPCR Primer Sequences See Table S7 for sequences  
Recombinant DNA 
TRE3G-Etv5-p2A-Tcf3-pGK-Hygo This study N/A 
CAG-Etv5-3xFlag-pGK-Hygro This study N/A 
CAG-ΔN-Etv5- 3xFlag-pGK-Hygro This study N/A 
CAG-mKusabira Orange-pGK-Hygro This study N/A 
CAG-Rbpj-pGK-Hygro This study N/A 
CAG-H2B-tdTomato-IRES-Puromycin This study N/A 
px459_SpCas9-2A-Puro  Addgene  #62988 
Software and Algorithms 
Bowtie2 Langmead and Salzberg, 
2012 
 
MACS2 Zhang et al., 2008  














Trim Galore!  Felix Krueger, 2015 https://www.bioinformatics.babraha
m.ac.uk/projects/trim_galore/ 





Samtools Li et al., 2009  http://samtools.sourceforge.net/ 
FeatureCounts  Liao et al., 2014 doi: 10.1093/bioinformatics/btt656 
R R Core Team, 2017 https://www.R-project.org/ 
DESeq2 Love et al., 2014 https://www.bioconductor.org/packa
ges/release/bioc/html/DESeq2.html 
Goseq Young et al., 2010 https://www.bioconductor.org/packa
ges/release/bioc/html/goseq.html 
Pheatmap Raivo Kolde, 2015 https://CRAN.R-
project.org/package=pheatmap 
Other 
N/A   
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Supplemental Figure Legends 
 
Figure S1. ETV4/5 expression and function (Related to Figure 1)  
(A) RNA-seq (data from Kalkan et al, 2017) and H3K4me3 ChIP-seq (this study) genome 
tracks for Etv5.  
(B) Western blot with polyclonal ETV5 antibody for detection of endogenous ETV5 in RGd2 
ESC. 2i cultures (0h) were switched to fresh 2i (2i), N2B27 (N) or single inhibitors (CH) or 
(PD) for 16 hours. Cells were transfected with negative control siRNA or siRNA against Etv5.  
(C, D) Relative growth rates of: wildtype and Etv4/5-dKO ESC from Lu et al, 2009; RGd2 
and Etv5-KO ESC lines. Cell numbers are normalized to WT for panel C, and to parental 
RGd2-1 ESC for panel D. Error bars indicate standard deviation (SD) from 2 wells cultured in 
parallel.  
(E) Restoration of Rex1-GFPd2 downregulation kinetics in two Etv5-KO clonal ESC lines 
carrying stable transgenes encoding ΔN and canonical isoforms of ETV5. 
(F) RT-qPCR for ETV4 in 2i and at indicated hours after 2i withdrawal. Error bars indicate 
SD from two wells cultured in parallel. 
 
Figure S2. RBPJ expression and function (Related to Figures 1 and 2)  
(A, B) TCF3 transcript levels in RGd2 and Etv5-KO ESCs in 2i and at hours (h) post-2i 
withdrawal.  
(C-F) RBPJ transcript levels in: the early mouse embryo; RGd2 and Etv5-KO ESCs in 2i and 
hours (h) after 2i withdrawal; RGd2 and mutant ESCs cultured in CH/L and 28h after CH/LIF 
withdrawal. Error bars indicate SD from 2 or 3 biological replicates for RNA-seq, or from 2 
wells cultured in parallel for RT-qPCR. 
(G) Phase contrast images of parental, Rbpj KO and transgene rescued ESC; MT=empty 
vector, Rbpj tg=transgene encoding RBPJ. Scale bar= 0.75 µm  
(H) Growth rates of two different RGd2 and Rbpj-KO ESC lines. All cell numbers were 
normalized to RGd2-1 ESC line.  
(I) Restoration of Rex1-GFPd2 downregulation in Rbpj-KO ESC line stably expressing Rbpj 
transgene.  
(J, K) Transcript levels of Notch target genes, and Notch pathway components.  
(L) GFP profiles of RGd2 ESCs treated with Notch inhibitors (iNotch) or DMSO: (1) before 2i 
withdrawal; (2) after 2i withdrawal; (3) before and after 2i withdrawal. 
 
Figure S3. RBPJ expression and function (Related to Figure 2)  
(A, B) KEGG pathway enrichment for differentially expressed genes in Rbpj mutants vs. 
parental RGd2 ESC in 2i, and in N16h.  
(C) Relative expression of genes associated with ECM and cell adhesion identified by KEGG 
pathway enrichment analysis.  
(D) MA-plot showing mean expression against fold change per gene in Rbpj-KO ESC in 2i. 
Gene symbols are shown for indicated genes.  
(E) Heatmaps showing relative expression of TOP 50 differentially expressed genes with 
mean FPKM≥1 in Rbpj-KO N16h for UP genes, and FPKM≥1 in RGd2 N16h for DOWN 
genes. Genes were ordered according to fold change of mean RNA-seq count in Rbpj-KO 




Supplemental Text and Figures
Figure S4. RBPJ expression and function (Related to Figures 2 and 3)  
(A) Expression of HES1 and ID factors in Rbpj mutants. Error bars show SD for 3 
independent clonal lines for Rbpj-KO, and 2 different lines for RGd2 (one parental, one 
clonal) cultured in parallel. 
(B, C) Rex1-GFPd2 profiles of Id3 knock-out, and Hes1 knock-out ESC. Data are shown for 
independent clonal lines cultured in parallel.  
(D) ChIP-qPCR for RBPJ-bound loci identified by Lake et al, 2014. Hes1 TSS and gene 
desert sites were used as positive and negative control regions, respectively. Rbpj-KO ESCs 
were used as negative control. Values were normalized to input DNA. Asterisks mark 
enrichment in Nanog and Tbx3 promoter proximal sites. Error bars indicate SD from 2 qPCR 
replicates. 
(E) GFP profiles at 29h after 2i withdrawal following a 7-hour period of siRNA transfection.  
(F) Venn diagram showing the overlap of upregulated genes in Rbpj-KO ESCs at 16h post-2i 
withdrawal from RNA-seq (this study) and RBPJ-associated genes from published ChIP-seq 
dataset. Only genes that show a fold change of ≥1.5 increase in Rbpj-KO over RGd2 are 
considered. Pluripotency regulators are shown in boxes and naïve pluripotency transcription 
factors are in bold. 
(G)  Venn diagram showing intersection of potential targets repressed by RBPJ and TCF3. 
(H) GFP profiles of parental RGd2 ESC, Etv5/Rbpj single and double mutants in CHIR99021 
(CH) only. Crossed box indicates failure of expansion after passage 2 (p2).  
(I) Growth rates of RGd2 ES cells in 2i, Etv5/Rbpj single and double mutants in CH. Error 
bars indicate SD from two independently-derived lines cultured in parallel.  
(J) Colony formation by RGd2 and ER-dKO ES cells in CH or CH/LIF after culture for 2 
passages (p2) in CH only.  Zoomed-in images show larger colonies from ER-KO ESCs.  
 
Figure S5. Dual and triple knock out phenotypes (Related to Figure 3)  
(A) Bright field images of mutant lines taken using a 20x objective.  
(B, C) Relative growth rates of indicated ESC over 5 passages in CH/L, and of RGd2 in 2i or 
ETR-tKO in N2B27. Independently derived ESC lines are numbered (1-3).  
(D) Flow cytometry profiles (a, c, e) of mixed cultures comprised of unlabelled RGd2 ESCs 
and  mKO-labelled RGd2 or mKO-labelled ETR-KO ESCs, and corresponding GFP profiles 
(b, d, f) of unlabelled RGd2 ESCs gated out from mixed cultures with mKO RGd2 (gray) or 
mKO ETR-KO ESC (light red).  
(E) GFP profiles for ETR-KO cells with Doxycline inducible Etv5-p2A-Tcf3 (iEp2aT) 
transgene expression.  
(F) RT-qPCR at 52h post-2i withdrawal and Doxycycline (dox) addition (100ng/ml). Error bar 
show SD from 2 qPCR replicates. 
(G) IF images for NANOG at 3 days post-2i withdrawal and Doxycycline (dox) addition 
(100ng/ml) taken using a 10x objective. 
 
Figure S6. ETV5 association with transcriptionally dynamic genes (Related to Fig 7)  
(A) Distribution of unique ETV5 ChIP-seq peaks in 2i and N16h samples. See STAR 
Methods for peak selection and classification.  
(B) Heatmap for relative expression of genes associated with ETV5 that are up- and 
downregulated in 2i.  
(C) Heatmap for ETV5 associated genes upregulated at 16h post-2i withdrawal (N16h). Only 
genes that show a fold change of ≥1.5 in the UP direction and ≤0.66 in the DOWN direction 
in Etv5-KO over RGd2 are considered. Expression shown as the log2 difference to the mean 
across all samples. 
(D) Venn diagrams showing the intersection of TCF3 and RBPJ targets with ETV5-bound, 
upregulated genes in Etv5-KO ESCs. Pluripotency regulators are shown in boxes and naïve 
pluripotency factors are in bold case. 
 
Figure S7. ETV5 association with transcriptionally dynamic genes (Related to Fig7)  
(A) RT-qPCR for Otx2 in parental RGd2 and Etv5-KO ESCs upon 2i withdrawal, h=hour. 
Relative expression normalized to GAPDH is shown. Error bars show SD from 2 wells of the 
same ESC line cultured in parallel. 
(B) ChIP-qPCR for ETV5 binding on putative enhancers shown in Fig 7C-E. ChIP was 
performed in duplicate (1-2) on ETV5-C-3xFlag knock-in RGd2 cells using an anti-Flag 
antibody. Error bars indicate SD from 2 qPCR replicates.  
(C) Western blot for POU3F1 and LEF1 in RGd2 ESC and Pou3f1/Lef1 single and double 
knock-out clonal ESC lines. Black line indicates where two halves of the blot were merged 
after removal of two lanes from a mistargeted clone. 
(D) GFP profiles in N2B27 at 26h post-2i withdrawal (N26h).  
(E) RT-qPCR at 48h post-2i withdrawal. Error bars show SD from 2 qPCR replicates. Data 
from 2 independently derived Lef1/Pou3f1-dKO (LP-dKO) clonal lines are presented. 
(F) UCSC Genome browser tracks showing normalized ChIP-seq read coverage for Etv5 
and H3K4me3 (this study), p300, H3K27Ac and H3K4me1 (Buecker et al , 2014) 
(G) RT-qPCR for Oct4 in 2iLIF and EpiLC on RGd2 and Etv5-KO ESCs (2 independent 
clonal lines). Error bars show SD from 2 technical replicates for qPCR. 
(H) Mean read coverage for p300, H3K27Ac and H3Kme1 (from Buecker et al, 2014) on 




Supplemental Tables  
 
Supplemental Table S1. Differentially expressed genes in Rbpj mutants and intersection 
with genes repressed by RBPJ and TCF3 (Related to Figures 2 and S4) 
Supplemental Table S2. Expression of all genes in the RNA-seq datasets (Related to 
Figure 5) 
Supplemental Table S3. Differentially expressed genes in ETR-KO Np5 vs. RGd2 2ip5 
(Related to Figure 5) 
Supplemental Table S4. Summary of phenotypes in chimeric embryos (Related to figure 6) 
Supplemental Table S5. ETV5-associated genomic loci (Related to Figure 7) 
Supplemental Table S6. Differentially expressed genes in Etv5 mutants and intersection 
with genes regulated by ETV5, RBPJ and TCF3 (Related to Figures 7 and S6) 
Supplemental Table S7. Reagents (Related to STAR Methods) 
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Rex1:GFPd2 profiles in CHIRON (CH)
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Figure S7 (Related to Fig 7)
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Oct4 proximal enhancer (-1524 to -30bp)













Chimeras Description / 
Classification 
E4.5 
WT 5 NA NA 100% (5/5) High contribution 
exclusively to ICM 
KO 9 NA NA 100%  
(9/9) 
High contribution 
exclusively to ICM 
E6.5 
WT 5 5 (1) 100 % (5/5) 100% (5/5) High contribution to 
epiblast (5/5); 
None Rex1 positive;  









Moderate contribution to 
epiblast (7/7); 
Rex1 signal in majority  of 
injected cells (7/7); 







Abnormal:  3/7 
E7.5 




High contribution of 
injected cells (13/13); 
No Nanog signal detected 
in 16/16 embryos; 
Pou3f1 signal in anterior 
epiblast (8/8); 
T signal in the primitive 
stream region (8/8); 
Normal: 16/16  
Retarded: 0/16 
Abnormal: 0/16 








Recipient failure for 2/4 
hosts; 
Mild to moderate 




High Nanog in majority of 
injected cells (13/13); 
scattered Pou6f1 signal in 
the epiblast (7/7), but not 
in injected cells; 
T expression (0/6); 
Normal: 0/13 
Retarded: 0/13 
Abnormal: 13/13  
Normal: No apparent developmental defects 
Abnormal: Malformed embryos 
Retarded: Small, but normal morphology  
 
All chimaeras were generated by microinjection of 8 cells into E2.5 embryos. 
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